INV-1120 is under clinical development by Ionova Life Science and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs for Sarcomas have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INV-1120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INV-1120 is under development for the treatment of cancer, solid tumors including colorectal, breast, pancreatic, lung cancer, sarcoma and liver cancers. It is administered orally. It acts by targeting EP4.
Ionova Life Science overview
Ionova Life Science, is a biotechnology company that develops anti-tumor and tumor immunomodulatory drugs for the treatment of oncology, immuno-oncology, and cardiac metabolic diseases. The company is headquartered in China.
For a complete picture of INV-1120’s drug-specific PTSR and LoA scores, buy the report here.